(S)-3-(biphenyl-4-sulfonyl)-thiazolidine-2-carboxylic acid [(S)-1-(4-fluoro-phenyl)-3-hydroxypropyl]amide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-3-(biphenyl-4-sulfonyl)-thiazolidine-2-carboxylic acid [(S)-1-(4-fluoro-phenyl)-3-hydroxypropyl]amide
• 英文别名: 3-(biphenyl-4-sulfonyl)thiazolidine-2-carboxylic acid [1-(4-fluorophenyl)-3-hydroxypropyl]amide；(2S)-N-[(1S)-1-(4-fluorophenyl)-3-hydroxypropyl]-3-(4-phenylphenyl)sulfonyl-1,3-thiazolidine-2-carboxamide
• 化学式: C₂₅H₂₅FN₂O₄S₂
• 分子量: 500.615
• InChiKey: VLKPHJQULXJQSP-ZCYQVOJMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (S)-3-(biphenyl-4-sulfonyl)-thiazolidine-2-carboxylic acid [(S)-1-(4-fluoro-phenyl)-3-hydroxypropyl]amide 在 4-二甲氨基吡啶 、 碳酸氢钠 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-amino-3-methylbutyric acid 3-{[3-(biphenyl-4-sulfonyl)thiazolidine-2-carbonyl]amino}-3-(4-fluorophenyl)propyl ester
  参考文献：
  名称：

  α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

  摘要：

  本发明提供了一种羟丙基噻唑啉羧酰胺衍生物的α-氨基酯，即(2S)-3-([1,1'-联苯]-4-基磺酰基)-N-[(1S)-3-羟基-1-苯基丙基]-1,3-噻唑啉-2-羧酰胺，以及其盐和晶体多态体，可用于抑制前列腺素F受体。本发明还涵盖了通过向需要治疗的患者投药这些物质来治疗早产等疾病的方法。

  公开号：

  US09447055B1
• 作为产物：
  描述：

  2-amino-3-methylbutyric acid 3-{[3-(biphenyl-4-sulfonyl)thiazolidine-2-carbonyl]amino}-3-(4-fluorophenyl)propyl ester 在 Endogenous esterases 作用下， 生成 (S)-3-(biphenyl-4-sulfonyl)-thiazolidine-2-carboxylic acid [(S)-1-(4-fluoro-phenyl)-3-hydroxypropyl]amide
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR
  [FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT OU DE PRÉVENTION DE TRAVAIL PRÉMATURÉ

  摘要：

  The disclosure provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks. Using the compositions and methods described herein, such subjects may be administered atosiban in combination with a prostaglandin F2α (PGF2α) antagonist. Exemplary PGF2α receptor antagonists that may be used for the treatment or prevention of preterm labor as described herein include 1,3-thiazolidine-2-carboxamide compounds, such as (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate hydrochloride). The compositions and methods described herein provide various clinical benefits. Delivery at an early gestational age is a leading cause of perinatal mortality. By delaying labor in pregnant human patients at an early gestational age, the compositions and methods of the disclosure provide unborn infants with additional time to develop vital organs and tissue systems, thereby significantly improving the likelihood of survival following delivery. The compositions and methods described herein may be used to delay the onset of delivery by one or more hours, days, or weeks, for example, so as to enable pregnant subjects to reach a gestational age at which parturition is substantially safer.

  公开号：

  WO2022101495A1

文献信息

• [EN] THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR<br/>[FR] DERIVES DE THIAZOLIDINE CARBOXAMIDE UTILES EN TANT QUE MODULATEURS DU RECEPTEUR DE PROSTAGLANDINE F
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2003082278A1

  公开（公告）日：2003-10-09

  The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. G is selected from the group consisting of C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C1-C6 Alkyl cycloalkyl, C1-C6-alkyl heteroaryl, aryl, heteroaryl, C3-C8-cycloalkyl or -heterocyclo­alkyl, said cycloalkyl or aryl or heteroaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups. R1 is selected from the group consisting of aryl, heteroaryl, C3-C8-cycloalkyl or - heterocyclo-alkyl, said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)cycloalkyl or aryl or heteroaryl groups. R2 is selected from the group consisting of H, carboxy, acyl, alkoxycarbonyl, amino­carbonyl, C1-C5-alkyl carboxy, C1-C5-alkyl acyl, C1-C5-alkyl alkoxycarbonyl, C1-C5-alkyl aminocarbonyl, C1-C5-alkyl acyloxy, C1-C5-alkyl acylamino, C1 -C5-alkyl ureido, C1-C5alkyl amino, C1-C5-alkyl alkoxy, C1-C5-alkyl sulfanyl, C1-C5-alkyl sulfinyl, C1-C5-alkyl sulfonyl, C1-C5-alkyl sulfonylamino, C1-C5-alkyl sulfonyloxy, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, heterocycloalkyl, C1-C6-alkyl aryl, C2-C6-alkyl heteroaryl, C1-C6-alkyl cycloalkyl, C1-C6-alkyl heterocycloalkyl, C2-C6-alkenyl aryl, C2-C6-alkenyl heteroaryl, C2-C6-alkynyl aryl, or C2-C6-alkynyl heteroaryl.

  本发明涉及公式（II）的噻唑烷羧酰胺衍生物，用于治疗和/或预防早产、早产、痛经以及在剖腹产前停止分娩。G选自C1-C6烷基芳基、C1-C6烷基杂芳基、C1-C6烷基环烷基、C1-C6烷基杂芳基、芳基、杂芳基、C3-C8环烷基或-杂环烷基，所述环烷基或芳基或杂芳基基团可能与环烷基或芳基或杂芳基基团融合。R1选自芳基、杂芳基、C3-C8环烷基或-杂环烷基，所述（杂）环烷基或芳基或杂芳基基团可能与（杂）环烷基或芳基或杂芳基基团融合。R2选自H、羧基、酰基、烷氧羰基、氨基羰基、C1-C5烷基羧基、C1-C5烷基酰基、C1-C5烷基烷氧羰基、C1-C5烷基氨基羰基、C1-C5烷基酰氧基、C1-C5烷基酰胺基、C1-C5烷基脲基、C1-C5烷基氨基、C1-C5烷基烷氧基、C1-C5烷基硫醇基、C1-C5烷基亚砜基、C1-C5烷基磺酰基、C1-C5烷基磺酰胺基、C1-C5烷基磺酰氧基、C1-C6烷基、C2-C6烯基、C2-C6炔基、芳基、杂芳基、C3-C8环烷基、杂环烷基、C1-C6烷基芳基、C2-C6烷基杂芳基、C1-C6烷基环烷基、C1-C6烷基杂环烷基、C2-C6烯基芳基、C2-C6烯基杂芳基、C2-C6炔基芳基或C2-C6炔基杂芳基。
• Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor
  申请人：Page Naxos Patrick

  公开号：US20050215605A1

  公开（公告）日：2005-09-29

  The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. G is selected from the group consisting of C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 1 -C 6 Alkyl cycloalkyl, C 1 -C 6 -alkyl heteroaryl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl or -heterocycloalkyl, said cycloalkyl or aryl or hetetoaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups. R 1 is selected from the group consisting of aryl, heteroaryl, C 3 -C 8 -cycloalkyl or -heterocyclo-alkyl, said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)cycloalkyl or aryl or heteroaryl groups. R 2 is selected from the group consisting of H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, C 1 -C 5 -alkyl carboxy, C 1 -C 5 -alkyl acyl, C 1 -C 5 -alkyl alkoxycarbonyl, C 1 -C 5 -alkyl aminocarbonyl, C 1 -C 5 -alkyl acyloxy, C 1 -C 5 -alkyl acylamino, C 1 -C 5 -alkyl ureido, C 1 -C 5 alkyl amino, C 1 -C 5 -alkyl alkoxy, C 1 -C 5 -alkyl sulfanyl, C 1 -C 5 -alkyl sulfinyl, C 1 -C 5 -alkyl sulfonyl, C 1 -C 5 -alkyl sulfonylamino, C 1 -C 5 -alkyl sulfonyloxy, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl, heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 2 -C 6 -alkyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, or C 2 -C 6 -alkynyl heteroaryl.

  本发明涉及式（II）的噻唑烷羧酰胺衍生物，用于治疗和/或预防早产、早产、痛经以及在剖腹产前停止分娩。其中，G选择自C1-C6烷基芳基，C1-C6烷基杂芳基，C1-C6烷基环烷基，C1-C6烷基杂环烷基，芳基，杂芳基，C3-C8环烷基或-杂环烷基，所述环烷基或芳基或杂芳基基团可以与环烷基或芳基或杂芳基基团融合。R1选择自芳基，杂芳基，C3-C8环烷基或-杂环烷基，所述（杂）环烷基或芳基或杂芳基基团可以与（杂）环烷基或芳基或杂芳基基团融合。R2选择自H，羧基，酰基，烷氧羰基，氨基羰基，C1-C5烷基羧基，C1-C5烷基酰基，C1-C5烷基烷氧羰基，C1-C5烷基氨基羰基，C1-C5烷基酰氧基，C1-C5烷基酰胺基，C1-C5烷基脲基，C1-C5烷基氨基，C1-C5烷基烷氧基，C1-C5烷基硫醇基，C1-C5烷基亚砜基，C1-C5烷基磺酰基，C1-C5烷基磺酰胺基，C1-C5烷基磺酰氧基，C1-C6烷基，C2-C6烯基，C2-C6炔基，芳基，杂芳基，C3-C8环烷基，杂环烷基，C1-C6烷基芳基，C2-C6烷基杂芳基，C1-C6烷基环烷基，C1-C6烷基杂环烷基，C2-C6烯基芳基，C2-C6烯基杂芳基，C2-C6炔基芳基或C2-C6炔基杂芳基。
• THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR
  申请人：PAGE Patrick Naxos

  公开号：US20080255094A1

  公开（公告）日：2008-10-16

  The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery.

  本发明涉及式（II）的噻唑烷羧酰胺衍生物，用于治疗和/或预防早产、早产、痛经以及在剖腹产前停止分娩。
• Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
  申请人：Merck Serono S.A.

  公开号：US10259795B2

  公开（公告）日：2019-04-16

  The invention provides α-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.

  本发明提供了可用于抑制前列腺素F受体的羟丙基噻唑烷甲酰胺衍生物(2S)-3-([1,1′-联苯]-4-基磺酰基)-N-[(1S)-3-羟基-1-苯基丙基]-1,3-噻唑烷-2-甲酰胺的α-氨基酯及其盐类和晶体多晶型物。本发明还包括通过向需要治疗的患者施用这些物质来治疗妊娠早期早产等疾病的方法。
• Compositions and methods for delaying the incidence of labor
  申请人：ObsEva S.A.

  公开号：US11534428B1

  公开（公告）日：2022-12-27

  The invention provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks. Using the compositions and methods described herein, such subjects may be administered nifedipine in combination with a prostaglandin F2α (PGF2α) antagonist. Exemplary PGF2α receptor antagonists that may be used for the treatment or prevention of preterm labor as described herein include 1,3-thiazolidine-2-carboxamide compounds, such as (3S)-3-([(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-([(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate hydrochloride. Using the compositions and methods described herein, a subject may be dosed with a PGF2α receptor antagonist and a reduced amount or frequency of nifedipine relative to the amount or frequency of nifedipine that would otherwise be used if the nifedipine were given in the absence of the PGF2α receptor antagonist.

  本发明提供了用于延缓妊娠受试者（如怀孕的人类受试者）在孕龄约24周至约34周时发生早产或有发生早产风险的组合物和方法。使用本文所述的组合物和方法，可将硝苯地平与前列腺素 F2α (PGF2α)拮抗剂联合给药。可用于治疗或预防本文所述早产的示例性 PGF2α 受体拮抗剂包括 1,3-噻唑烷-2-甲酰胺化合物，如 (3S)-3-([(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate 或其药学上可接受的盐（例如：(3S)-3-([(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-噻唑烷-2-基]羰基}-氨基}-3-(4-氟苯基)丙基）、(3S)-3-([(2S)-3-(联苯-4-基磺酰基)-1,3-噻唑烷-2-基]羰基}-氨基)-3-(4-氟苯基)丙基 L-缬氨酸盐酸盐。使用本文所述的组合物和方法，可向受试者施用 PGF2α 受体拮抗剂和硝苯地平，相对于在没有 PGF2α 受体拮抗剂的情况下施用硝苯地平的用量或次数而言，可减少硝苯地平的用量或次数。